Novartis Launches Virtual Innovation Hub to Accelerate Digital Health Solutions in Sub-Saharan Africa

Copyright 2021 PR Newswire. All rights reserved
2021-11-25

NAIROBI, Kenya, 25 November 2021 / PRNewswire / – Novartis has announced the launch of its new innovation hub, Novartis Biome Sub-Saharan Africa (SSA), which will spearhead the development of innovative business models and technology solutions to improve healthcare in the region. The cluster will focus on intersectoral partnerships to accelerate innovative approaches in order to increase affordable access to high-quality medicines and to strengthen health systems in the long term.

“Our goal is to provide every patient in SSA with affordable access to high quality medicines and ultimately to transform healthcare in the region. To this, innovation and digital technologies have immense potential to contribute, and with cross-sector partnerships, we can truly maximize the impact on the health of our people, ”said Racey Muchilwa, President and Director, Novartis Sub-Saharan Africa.

Recognizing that access to medicines remains one of the greatest global healthcare challenges, and with Africa Home to the world’s largest underserved population, Novartis Biome SSA will focus on four strategic priorities:

1) extend the accessibility of health care

2) strengthen early diagnosis to achieve better results

3) leader in supply chain innovation

4) support the education of healthcare professionals and patient awareness

Working on these four priorities supports Novartis’ aspiration to double its patient reach in sub-Saharan Africa by 2022 and increase it fivefold by 2025.

“While healthcare innovation is at the heart of our work at Novartis, we know that no single company can solve these challenges alone. Building strong partnerships and fostering greater collaboration is the only way to make meaningful and transformative access improvements in our region, ”continued Muchilwa.

Influence affordability, access and outcomes through partnerships

Novartis Biome SSA will also continue to develop its partnership with Medtronic Laboratories providing end-to-end care for patients with hypertension and diabetes by seeking to scale their model across the continent and working with major international organizations as well as with local implementation champions. The digital solution powered by Medtronic gives physicians the ability to proactively manage large patient cohorts and act on red alerts, as well as give patients the ability to join virtual patient support groups.

In addition, Novartis has in partnership with the Commonwealth Pharmacists Association (CPA) to support the training of more than one million pharmacists in the 54 Commonwealth countries, of which more than 20 are from sub-Saharan Africa and supported by Novartis Biome SSA.

Disclaimer This media update contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential”, “may”, “will”, “plan” , “” Could “,” could “,” would like “,” expect “,” anticipate “,” seek “,” look forward to “,” believe “,” commit “,”, “goals” or similar terms, or by express or implied discussions concerning possible marketing authorizations, new indications or new labeling for experimental or approved products, or concerning the potential future revenues of such a launch of the division digital innovation. You should not place undue reliance on these statements. These forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to important known and unknown risks and uncertainties. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove to be incorrect, actual results could differ materially from those stated in forward-looking statements. Novartis is providing the information contained in this media update as of this date and makes no commitment to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis Biome

A catalyst for impactful digital collaboration, the Novartis Biome is a network of 15 innovation hubs in targeted strategic locations that helps teams successfully partner, develop and scale digital solutions for improve and prolong the life of patients. With over 65 digital innovators, supported by a community of over 125 leaders from our enabling functions, Novartis Biome brings together the best of science and technology to create better healthcare solutions and better patient experiences. , in large scale. Examples include a clinical test mobile app designed to help monitor vision from a distance, and a point-of-service diagnostic solution for sickle cell anemia. Learn more about www.biome.novartis.com .

About Novartis Sub-Saharan Africa

Novartis Sub-Saharan Africa (SSA) provides healthcare solutions that improve and extend people’s lives. We use scientific innovation to solve some of the most difficult health problems in society. We discover and develop breakthrough treatments and find new ways to deliver them to as many patients as possible. Novartis SSA comprises 46 countries and is headquartered in Nairobi, Kenya. The ASS is grouped into Cluster East Africa, English-speaking West Africa, French-speaking West Africa and central Africa, and the Southern Africa Cluster. Learn more about: Sub-Saharan Africa | Novartis

Novartis Data and Digital
Novartis is positioned as a leading pharmaceutical company powered by advanced therapies and data science. Go big on data and digital is a key strategic pillar that helps Novartis achieve this ambition. Data science and digital technologies allow the company to reinvent the way to innovate in R&D, to interact with patients and customers and to increase operational efficiency. Learn more about novartis.com.

Show original content:https://www.prnewswire.com/news-releases/novartis-launches-virtual-innovation-hub-to-accelerate-digital-health-solutions-in-sub-saharan-africa-301432078.html

SOURCE Novartis



Source link

Comments are closed.